In the Original Investigation titled “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial,”1 published January 13, 2021, there were errors in the Discussion section. The penultimate sentence of the first paragraph should have referred to a 0.8% weight loss among patients receiving placebo. The final sentence should have read that weight loss with bimagrumab was greater than the 1-year FDA threshold of 5% for registration of new medicines for treating obesity and overweight. This article has been corrected.1
Error in Discussion. JAMA Netw Open. 2021;4(2):e211376. doi:10.1001/jamanetworkopen.2021.1376
Customize your JAMA Network experience by selecting one or more topics from the list below.